London, England – 10th August 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research...

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors London, England – 18th July 2022 -...

Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases Company emerges out of stealth mode...